Emerging role of cysteinyl LTs in cancer - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles British Journal of Pharmacology Year : 2022

Emerging role of cysteinyl LTs in cancer


Cysteinyl leukotrienes (CysLTs) are inflammatory lipid mediators that play a central role in the pathophysiology of several inflammatory diseases. Recently, there has been an increased interest in determining how these lipid mediators orchestrate tumour development and metastasis through promoting a pro-tumour micro-environment. Up-regulation of CysLTs receptors and CysLTs production is found in a number of cancers and has been associated with increased tumorigenesis. Understanding the molecular mechanisms underlying the role of CysLTs and their receptors in cancer progression will help investigate the potential of targeting CysLTs signalling for anti-cancer therapy. This review gives an overview of the biological effects of CysLTs and their receptors, along with current knowledge of their regulation and expression. It also provides a recent update on the molecular mechanisms that have been postulated to explain their role in tumorigenesis and on the potential of anti-CysLTs in the treatment of cancer.



Dates and versions

inserm-03847804 , version 1 (10-11-2022)



Lou Saier, Olivier Peyruchaud. Emerging role of cysteinyl LTs in cancer. British Journal of Pharmacology, 2022, 179 (22), pp.5036-5055. ⟨10.1111/bph.15402⟩. ⟨inserm-03847804⟩
2 View
0 Download



Gmail Facebook Twitter LinkedIn More